Calidi Biotherapeutics Inc. (NYSE American: CLDI) has been featured in a recent editorial highlighting its innovative precision genetic medicine platform. This platform is designed to target both primary and metastatic cancer tumors using engineered viruses, offering a novel approach in the fight against cancer. With global cancer diagnoses expected to soar to 35 million annually by 2050, Calidi's technology could not only meet critical unmet needs but also transform the landscape of cancer treatment.
The company's platform stands out for its ability to deliver potent genetic therapies directly to cancer sites. This method promises to enhance the efficacy of treatments while improving patient safety, marking a significant step forward in oncology. Calidi Biotherapeutics' approach leverages engineered viruses carried by allogeneic stem cells, targeting high-grade gliomas and solid tumors, and potentially preventing metastatic disease.
For more information on Calidi Biotherapeutics and its groundbreaking work, visit https://www.calidibio.com. The company's latest developments and updates are also available in its newsroom at https://ibn.fm/CLDI.
